Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis

References

• Papers of special note have been highlighted as either of interest or of considerable interest to readers.
   Google Scholar
• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22(3):557–65.
   PubMed Web of Science ®Google Scholar
• Comprehensive review on TNF-α inhibitors
   Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 2003;3(3):323–8.
   PubMed Web of Science ®Google Scholar
• Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician. 2007;36(12):1035–8.
   PubMed Web of Science ®Google Scholar
• Comprehensive review concerning the clinical use of TNF-α inhibitors
   Google Scholar
• Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf. 2012;11(1):1–5.
   PubMed Web of Science ®Google Scholar
• Comprehensive article concerning current data upon efficacy and safety of TNF-α inhibitors
   Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011;11(1):56–60.
   PubMed Web of Science ®Google Scholar
• Comprehensive review upon the current biological drugs for the treatment of SLE
   Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today. 2011;47(4):277–88.
   PubMed Web of Science ®Google Scholar
• Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev. 2005;4:537–41.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opin Drug Saf. 2013;12(6):801–4.
   PubMed Web of Science ®Google Scholar
• Comprehensive paper upon combination regimens
   Google Scholar
• Murdaca G, Spanò F, Puppo F. Long-term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol. 2013;5:43–9.
   PubMedGoogle Scholar
• Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34(6):819–36.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F. Anti-numor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol. 2010;11(6):437–9.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, Guastalla A, Puppo F. Potential use of TNF-α inhibitors in systemic sclerosis. Immunotherapy. 2014;6(3):283–9.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spano F, Contatore M, Guastalla A, Magnani O, Puppo F. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opin Drug Saf. 2014;13(5):649–61.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spano F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf. 2014;13(3):295–305.
   PubMed Web of Science ®Google Scholar
• Furst DE. Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64(Suppl. 4):iv2–14.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev. 2007;6(8):515–19.
   PubMed Web of Science ®Google Scholar
• Comprehensive paper upon the use of TNF-α inhibitors in Ps
   Google Scholar
• Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford). 2005;44(3):390–7.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interf Cytokine Res. 2012;32(6):277–9.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013;12(2):187–93.
   PubMed Web of Science ®Google Scholar
• Comprehensive review upon the injection site reactions
   Google Scholar
• Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14(4):571–82.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol. 2012;39(8):1583–602.
   PubMed Web of Science ®Google Scholar
• Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016;75(6):965–73.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol (Hoboken, NJ). 2015;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Prevention Committee of the Japanese Society for Tubercolosis; Treatment Committee of the Japanese Society for Tubercolosis. Treatment guidelines for latent tuberculosis infection. Kekkaku. 2014;89:21–37.
   PubMedGoogle Scholar
• Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667–75.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther. 2012;14(3):R147.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US food and drug administration warnings on hepatitis b reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703–11.
   PubMed Web of Science ®Google Scholar
• Asahina Y, Hayashi N, Hiramatsu N, Izumi N, Koike K, Kumada H, et al. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(Suppl.1):1–58.
   Web of Science ®Google Scholar
• Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–44.e3.
   PubMed Web of Science ®Google Scholar
• Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13(4):508–9.
   PubMed Web of Science ®Google Scholar
• Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol. 2006;12(6):974–6.
   PubMed Web of Science ®Google Scholar
• Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull. 2009;92(1):61–77.
   PubMed Web of Science ®Google Scholar
• Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31(6):931–6.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumour necrosis factor therapy. Clin Exp Rheumatol. 2013;31(1):118–21.
   PubMed Web of Science ®Google Scholar
• Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76(6):1051–6.
   PubMed Web of Science ®Google Scholar
• Comprehensive guidelines for screening before anti-TNFα treatment
   Google Scholar
• Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59(7):C4480.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.
   PubMed Web of Science ®Google Scholar
• Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62(11):1078–82.
   PubMed Web of Science ®Google Scholar
• Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol. 2010;134(2):113–20.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Orsi A, Spanò F, Puppo F, Durando P, Icardi G, Ansaldi F. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev. 2014;13(2):75–84.
   PubMed Web of Science ®Google Scholar
• Comprehensive review upon safety and immunogenicity of vaccinations
   Google Scholar
• Murdaca G, Orsi A, Spanò F, Faccio V, Puppo F, Durando P, et al. Vaccine-preventable infections in Systemic Lupus Erythematosus. Hum Vaccin Immunother. 2016;12(3):632–43.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med. 2011;6(6):487–95.
   PubMed Web of Science ®Google Scholar
• Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15(7):766–73.
   PubMed Web of Science ®Google Scholar
• Filaci G, Rizzi M, Setti M, Fenoglio D, Fravega M, Basso M, et al. Non-antigen-specific CD8+ T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci. 2005;1050:115–23.
   PubMed Web of Science ®Google Scholar
• Ceeraz S, Hall C, Choy EH, Spencer J, Corrigall VM. Defective CD8 + CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol. 2013;174(1):18–26.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Contatore M, Gulli R, Mandich P, Puppo F. Genetic factors and systemic sclerosis. Autoimmun Rev. 2016;15(5):427–32.
   PubMed Web of Science ®Google Scholar
• Booth AD, Jayne DRW, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109(14):1718–23.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012;224(2):309–17.
   PubMed Web of Science ®Google Scholar
• An interesting text that describe the beneficial effect of TNF-α inhibitors upon endothelial dysfunction
   Google Scholar
• Murdaca G, Spano F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF-alpha inhibitors. Redox Rep. 2013;18(3):95–9.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2009;8(4):309–15.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Murdaca G, Caiti M, Rodriguez G, Grassia L, Rossi E, et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:121–6.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy. 2008;63(7):945–6.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol. 2008;69(8):510–2.
   PubMed Web of Science ®Google Scholar
• Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension. 2005;46(1):76–81.
   PubMed Web of Science ®Google Scholar
• Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum. 2012;42(1):1–8.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009;5(12):677–84.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. Immunotherapy. 2013;5(2):113–15.
   PubMed Web of Science ®Google Scholar
• This paper describe the beneficial effect of TNF-α inhibitors upon endothelial dysfunction
   Google Scholar
• Murdaca G, Spanò F, Contatore M, Guastalla A, Magnani O, Puppo F. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10(12):1703–10.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, Mandich P, Puppo F. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? Drug Dev Res. 2014;75:S7–S10.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, Lantieri F, Burlando M, Parodi A, et al. TNF-α Gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–9.
   PubMed Web of Science ®Google Scholar
• This text describes the role of pharmacogenomics in TNF-α efficacy
   Google Scholar
• Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet. 2015;385:S48.
   PubMed Web of Science ®Google Scholar
• Kui R, Gál B, Gaál M, Kiss M, Kemény L, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. 2016;43(9):1018–23.
   PubMed Web of Science ®Google Scholar
• Keiserman M, Codreanu C, Handa R, Xibillé-Friedmann D, Mysler E, Briceño F, Akar S. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol. 2014;10:1049–1054.
   PubMed Web of Science ®Google Scholar
• Mok CC, Van Der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429–35.
   PubMed Web of Science ®Google Scholar
• Moll J, Haslock I, MacRae I, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343–64.
   PubMed Web of Science ®Google Scholar
• Dougados M, Landewé R. Spondyloarthritis: pathogenesis, clinical aspects and diagnosis. In: Bijlsma JWJ, ed. EULAR Compendium on Rheumatic Diseases. BMJ Publishing Group, London; 2009: 92–115.
   Google Scholar
• An interesting paper upon pathogenesis of spondyloarthritis
   Google Scholar
• Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–27.
   PubMed Web of Science ®Google Scholar
• An accurate paper upon classification and criteria of spondylorthritis
   Google Scholar
• Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63(5):1099–112.
   PubMed Web of Science ®Google Scholar
• Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford). 2015;54(1):20–8.
   PubMed Web of Science ®Google Scholar
• Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol. 2009;5(11):634–41.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl. 2):ii14–17.
   PubMed Web of Science ®Google Scholar
• Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36(2):361–7.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017;69(3):347–55.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.
   PubMed Web of Science ®Google Scholar
• Peranteau AJ, Turkeltaub AE, Tong Y, Nawas Z, Tyring SK. A Review of ixekizumab, an anti-interleukin-17A monoclonal antibody, for moderate-to-severe plaque psoriasis. Skin Therapy Lett. 2016;21(6):1–6.
   PubMedGoogle Scholar
• Olivieri I, D’angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9):531–42.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90.
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1999;42(11):2325–9.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44.
   PubMedGoogle Scholar
• Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–72.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712–21.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ãstergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382–90.
   PubMed Web of Science ®Google Scholar
• Iannone F, Lopriore S, Bucci R, Lopalco G, Chialà A, Cantarini L, Lapadula G. Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings. J Rheumatol. 2016;43(5):911–17.
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Zmierczak H-G, Helliwell PS. Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J Rheumatol. 2005;32(6):974–7.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Parsons WJ, Perrotta FM. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2016;43(5):918–23.
   PubMed Web of Science ®Google Scholar
• de Vlam K, Boone C. Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study). Clin Exp Rheumatol. 2015;33(5):624–31.
   PubMed Web of Science ®Google Scholar
• Interesting paper describing a trial upon etanercept efficacy on PsA
   Google Scholar
• Peluso R, Iervolino S, Vitiello M, Bruner V, Lupoli G, Di Minno MND. Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol. 2015;34(4):745–53.
   PubMed Web of Science ®Google Scholar
• Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(12):1729–35.
   PubMed Web of Science ®Google Scholar
• Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015;29(5):955–63.
   PubMed Web of Science ®Google Scholar
• Di Minno M, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost. 2012;38(5):497–505.
   PubMed Web of Science ®Google Scholar
• A complete paper describing cardiovascular risk in patients with PsA
   Google Scholar
• Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40(10):1868–72.
   PubMed Web of Science ®Google Scholar
• Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl. 3):12–29.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Visman IM, Peters MJL, Boers M, Dijkmans BAC, Nurmohamed MT. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):875–6.
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol. 2009;38(6):439–44.
   PubMed Web of Science ®Google Scholar
• Canete JD, Pablos JL, Sanmarti R, Mallofré C, Marsal S, Maymó J, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 2004;50(5):1636–41.
   PubMed Web of Science ®Google Scholar
• Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther. 2008;10(5):R125.
   PubMed Web of Science ®Google Scholar
• Avramidis G, Krüger-Krasagakis S, Krasagakis K, Fragiadaki I, Kokolakis G, Tosca A. The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br J Dermatol. 2010;163(5):928–34.
   PubMed Web of Science ®Google Scholar
• Campanati A, Orciani M, Gorbi S, Regoli F, Di Primio R, Offidani A. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. Br J Dermatol. 2012;167(1):68–76.
   PubMed Web of Science ®Google Scholar
• Kanbe K, Inoue K, Inoue Y, Suzuki Y. Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis. Clin Rheumatol. 2008;27(6):777–81.
   PubMed Web of Science ®Google Scholar
• Strunk J, Bundke E, Lange U. Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int. 2006;26(3):252–6.
   PubMed Web of Science ®Google Scholar
• Di Minno MND, Iervolino S, Zincarelli C, Lupoli R, Ambrosino P, Pizzicato P, et al. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opin Drug Saf. 2015;14(12):1905–13.
   PubMed Web of Science ®Google Scholar
• Di Minno MND, Iervolino S, Peluso R, Di Minno A, Ambrosino P, Scarpa R, et al. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis – effect of different treatments. J Rheumatol. 2014;41(4):714–22.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175–9.
   PubMed Web of Science ®Google Scholar
• Agirbasli M, Inanc N, Baykan OA, Direskeneli H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol. 2006;24(5):580–3.
   Google Scholar
• Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(2):254–7.
   PubMed Web of Science ®Google Scholar
• Puig L, Strohal R, Husni ME, Tsai TF, Noppakun N, Szumski A, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat. 2015;26(1):7–15.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33(6):833–9.
   PubMed Web of Science ®Google Scholar
• Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210–17.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–9.
   PubMed Web of Science ®Google Scholar
• van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895–900.
   PubMed Web of Science ®Google Scholar
• Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR. Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs. Arthritis Rheumatol (Hoboken, NJ). 2016;68(1):67–76.
   PubMed Web of Science ®Google Scholar
• Burrows NP, Norris PG, Alexander G, Wreghitt T. Chronic hepatitis C infection and psoriasis. Dermatology (Basel). 1995;190(2):173.
   PubMed Web of Science ®Google Scholar
• Chouela E, Abeldaño a, Panetta J, Ducard M, Neglia V, Sookoian S, et al. Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol. 1996;35(11):797–9.
   PubMed Web of Science ®Google Scholar
• Taglione E, Vatteroni ML, Martini P, Galluzzo E, Lombardini F, Delle Sedie A, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol. 1999;26(2):370–2.
   PubMed Web of Science ®Google Scholar
• Palazzi C, D’Angelo S, Olivieri I. Hepatitis C virus-related arthritis. Autoimmun Rev. 2008;8(1):48–51.
   PubMed Web of Science ®Google Scholar
• Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, et al. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther. 2015;15(5):641–50.
   PubMed Web of Science ®Google Scholar
• Zein NN. Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315–22.
   PubMed Web of Science ®Google Scholar
• Zanni M, Missale G, Santilli D, Nuzzo S. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol. 2011;21(4):564–7.
   PubMed Web of Science ®Google Scholar
• Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol. 2010;23(3):965–9.
   PubMed Web of Science ®Google Scholar
• Kim GW, Jin H, Cho HH, Mun JH, Song M, Kim HS, et al. Primary thyroid marginal zone b cell lymphoma in psoriatic arthritis patient treated with etanercept. J Dermatol. 2014;41:97.
   Web of Science ®Google Scholar
• Lezcano Carduz VP, Mingo Botin D, Duran Poveda SP. Squamous cell neoplasm of the ocular surface in a patient with psoriasis treated with tumor necrosis factor-alpha inhibitors. Cornea. 2015;34(7):833–4.
   PubMed Web of Science ®Google Scholar
• Jahangier ZN, Jacobs JWG, Kraan MC, Wenting MJ, Smeets TJ, Bijlsma JW, et al. Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids. Ann Rheum Dis. 2006;65(10):1286–92.
   PubMed Web of Science ®Google Scholar
• Aalbers C, Gerlag D, Vos K, Vervoordeldonk M, Landewé R, Tak PP. Intra-articular etanercept treatment in inflammatory arthritis: a randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment. Joint Bone Spine. 2015;82(5):338–44.
   PubMed Web of Science ®Google Scholar
• An interesting paper concerning the intrarticular administration of etanercept
   Google Scholar
• Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006;20(3):401–17.
   PubMed Web of Science ®Google Scholar
• Lee JH, Jun JB, Jung S, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci. 2002;17(5):669–73.
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007;66(8):1072–7.
   PubMed Web of Science ®Google Scholar
• Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, Triolo G. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30(11):1437–40.
   PubMed Web of Science ®Google Scholar
• Damjanov N, Shehhi WA, Huang F, Kotak S, Burgos-Vargas R, Shirazy K, et al. Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. Rheumatol Int. 2016;36(5):643–51.
   PubMed Web of Science ®Google Scholar
• Batteux B, Devauchelle A, Boyard PL, Sejourné A, Fardellone P, Goëb V. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study. Joint Bone Spine. 2016;83(5):607–9.
   PubMed Web of Science ®Google Scholar
• Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(9):1–334.
   PubMed Web of Science ®Google Scholar
• Heinonen AV, Aaltonen KJ, Joensuu JT, Lähteenmäki JP, Pertovaara MI, Romu MK, et al. Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol. 2015;42(12):2339–46.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Zack D, Wajdula J, Sridharan S, Koenig A. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scand J Rheumatol. 2014;43(1):49–53.
   PubMed Web of Science ®Google Scholar
• Li H, Li Q, Chen X, Ji C, Gu J. Anti-tumor necrosis factor therapy increased spine and femoral neck bone mineral density of patients with active ankylosing spondylitis with low bone mineral density. J Rheumatol. 2015;42(8):1413–17.
   PubMed Web of Science ®Google Scholar
• Yates M, Hamilton LE, Elender F, Dean L, Doll H, MacGregor AJ, et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J Rheumatol. 2015;42(7):1177–85.
   PubMed Web of Science ®Google Scholar
• Braun J, Van Der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63(6):1543–51.
   PubMed Web of Science ®Google Scholar
• Fafá BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, et al. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Clin Rheumatol. 2015;34(5):921–7.
   PubMed Web of Science ®Google Scholar
• Xiao P, Pang C, Zhu X, Wu X. Clinical research for curing ankylosing spondylitis through combining etanercept, thalidomide and sulfasalazine. Pak J Pharm Sci. 2015;28(Suppl.1):359–62.
   Web of Science ®Google Scholar
• Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology. 2009;48(9):1029–35.
   PubMed Web of Science ®Google Scholar
• Wang C, Feng Y, Ren Z, Yang X, Jia JF, Rong MY, et al. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy. Clin Rheumatol. 2015;34(6):1073–8.
   PubMed Web of Science ®Google Scholar
• Wu D, Guo Y-Y, Xu N-N, Zhao S, Hou LX, Jiao T, Zhang N. Efficacy of anti–tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015;16(1):19.
   PubMed Web of Science ®Google Scholar
• Shao H, Fu Y, Song L, Sun S, Kaplan HJ, Sun D. Lymphotoxin beta receptor-Ig fusion protein treatment blocks actively induced, but not adoptively transferred, uveitis in Lewis rats. Eur J Immunol. 2003;33(6):1736–43.
   PubMed Web of Science ®Google Scholar
• Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14(3):145–50.
   PubMed Web of Science ®Google Scholar
• Monnet D, Moachon L, Dougados M, Brézin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol. 2006;2(7):393–7.
   PubMedGoogle Scholar
• Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, Grootenboer-Mignot S, Ruimy R, Meyer O, Hayem G. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology. 2008;47(8):1160–7.
   PubMed Web of Science ®Google Scholar
• Moll C, Hernández MV, Cañete JD, Gómez-Puerta JA, Soriano A, Collado A, Sanmartí R. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum. 2008;37(5):299–306.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li Y, Li Y, Zhao H, Li H. Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with review of the relevant published work. J Dermatol. 2011;38(2):155–9.
   PubMed Web of Science ®Google Scholar
• Assmann G, Simon P. The SAPHO syndrome-are microbes involved? Best Pract Res Clin Rheumatol. 2011;25(3):423–34.
   PubMed Web of Science ®Google Scholar
• Sáez-Martín L-C, Gómez-Castro S, Román-Curto C, Palacios-Álvarez I, Fernández-López E. Etanercept in the treatment of SAPHO syndrome. Int J Dermatol. 2015;54(6):e206–8.
   PubMed Web of Science ®Google Scholar
• Su Y-S, Chang C-H. SAPHO syndrome associated with acne conglobata successfully treated with etanercept. J Formos Med Assoc. 2015;114(6):562–4.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Zhao JX, Liu XY. Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study. Rheumatol Int. 2012;32(7):1963–5.
   PubMed Web of Science ®Google Scholar
• Vilar-Alejo J, Dehesa L, de la Rosa-del Rey P, Novoa-Medina J, Valerón Almazán P, Santana Medina N, Bastida J. SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept. Acta Derm Venerol. 2010;90(5):531–2.
   PubMed Web of Science ®Google Scholar
• Ben Abdelghani K, Dran Dg Gottenberg J-E, Morel J, Sibilia J, Combe B. Tumor necrosis factor-blockers in SAPHO syndrome. J Rheumatol. 2010;37(8):1699–704.
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43(4):816–24.
   PubMed Web of Science ®Google Scholar
• Walters HM, Pan N, Lehman TJA, Adams A, Kalliolias GD, Zhu YS, et al. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol. 2016;184(3):308–17.
   PubMed Web of Science ®Google Scholar
• Weiss PF, Klink AJ, Behrens EM, Sherry DD, Finkel TH, Feudtner C, et al. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2011;63(9):1307–12.
   PubMed Web of Science ®Google Scholar
• Kahn R, Berthold E, Gullstrand B, Schmidt T, Kahn F, Geborek P, et al. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis. Acta Paediatr. 2016;105(4):427–32.
   PubMed Web of Science ®Google Scholar
• Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology. 2016;55(5):840–7.
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJS, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Vredeveld CM. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437.
   PubMed Web of Science ®Google Scholar
• Barthel D, Ganser G, Kuester R-M, Onken N, Minden K, Girschick HJ, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42(11):2160–5.
   PubMed Web of Science ®Google Scholar
• Anink J, Prince FHM, Dijkstra M, Otten MH, Twilt M, ten Cate R, et al. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford). 2015;54(11):1964–9.
   PubMed Web of Science ®Google Scholar
• Azevedo VF, Galli N, Kleinfelder A, D’Ippolito J, Urbano PCM. Etanercept biosimilars. Rheumatol Int. 2015;35(2):197–209.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Petersel D, Isakov L, Lula S, Lea Sewell K. Biosimilars for the treatment of chronic inflammatory diseases: a systematic review of published evidence. BioDrugs. 2016;30(6):525–70.
   PubMed Web of Science ®Google Scholar
• Prinz JC, Puig L, Girolomoni G. Treatment of psoriasis with etanercept: the typical patient profile. J Eur Acad Dermatol Venereol. 2016;30(7):1092–9.
   PubMed Web of Science ®Google Scholar
• Segaert S, Ghislain P-D, Boone C. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium). J Dermatolog Treat. 2016;27(2):103–9.
   PubMed Web of Science ®Google Scholar
• Moreno-Ramírez D, Ojeda-Vila T, Ferrándiz L. Disease control for patients with psoriasis receiving continuous versus interrupted therapy with adalimumab or etanercept: a clinical practice study. Am J Clin Dermatol. 2014;15(6):543–9.
   PubMed Web of Science ®Google Scholar